| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 13 | 2025 | 254 | 2.430 |
Why?
|
| Fibrinolytic Agents | 12 | 2018 | 205 | 1.900 |
Why?
|
| Transcatheter Aortic Valve Replacement | 10 | 2025 | 199 | 1.830 |
Why?
|
| Myocardial Infarction | 23 | 2020 | 1039 | 1.630 |
Why?
|
| Aortic Valve Stenosis | 10 | 2025 | 334 | 1.450 |
Why?
|
| Angioplasty, Balloon, Coronary | 14 | 2011 | 180 | 1.390 |
Why?
|
| Emergency Medical Services | 9 | 2020 | 395 | 1.390 |
Why?
|
| Thrombolytic Therapy | 10 | 2018 | 215 | 1.240 |
Why?
|
| Coronary Artery Disease | 6 | 2023 | 800 | 1.180 |
Why?
|
| Acute Coronary Syndrome | 4 | 2025 | 215 | 1.040 |
Why?
|
| Embolism | 2 | 2018 | 48 | 1.010 |
Why?
|
| Coronary Occlusion | 2 | 2018 | 29 | 1.000 |
Why?
|
| ST Elevation Myocardial Infarction | 4 | 2024 | 113 | 0.970 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2023 | 8 | 0.860 |
Why?
|
| Cardiology | 6 | 2023 | 505 | 0.780 |
Why?
|
| Aortic Valve | 8 | 2025 | 441 | 0.760 |
Why?
|
| Coronary Angiography | 15 | 2024 | 443 | 0.750 |
Why?
|
| Coronary Artery Bypass | 6 | 2023 | 514 | 0.730 |
Why?
|
| Lipectomy | 1 | 2018 | 8 | 0.600 |
Why?
|
| Embolism, Fat | 1 | 2018 | 6 | 0.600 |
Why?
|
| Denervation | 1 | 2017 | 29 | 0.560 |
Why?
|
| Treatment Outcome | 34 | 2025 | 12383 | 0.550 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2023 | 1119 | 0.540 |
Why?
|
| Myocardial Reperfusion | 3 | 2011 | 73 | 0.510 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2020 | 369 | 0.490 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 577 | 0.480 |
Why?
|
| Angina Pectoris | 5 | 2021 | 58 | 0.480 |
Why?
|
| Stents | 10 | 2024 | 887 | 0.480 |
Why?
|
| Humans | 82 | 2025 | 125014 | 0.460 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 508 | 0.450 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2015 | 141 | 0.440 |
Why?
|
| Angioplasty, Balloon | 3 | 2011 | 172 | 0.430 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 79 | 0.410 |
Why?
|
| Endocarditis, Bacterial | 1 | 2014 | 133 | 0.400 |
Why?
|
| Foramen Ovale, Patent | 2 | 2022 | 16 | 0.400 |
Why?
|
| Coronary Vessels | 9 | 2023 | 554 | 0.390 |
Why?
|
| Septal Occluder Device | 2 | 2022 | 42 | 0.380 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2018 | 270 | 0.380 |
Why?
|
| Recovery of Function | 1 | 2014 | 445 | 0.370 |
Why?
|
| Myocardial Ischemia | 3 | 2011 | 344 | 0.370 |
Why?
|
| Electrocardiography | 5 | 2020 | 977 | 0.350 |
Why?
|
| Kidney | 1 | 2017 | 1366 | 0.340 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2021 | 436 | 0.340 |
Why?
|
| Cardiac Catheterization | 8 | 2022 | 634 | 0.320 |
Why?
|
| Hospital Mortality | 5 | 2020 | 1025 | 0.310 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 560 | 0.310 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2021 | 44 | 0.300 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 64 | 0.300 |
Why?
|
| Stroke | 4 | 2022 | 986 | 0.290 |
Why?
|
| Aged | 25 | 2023 | 19854 | 0.290 |
Why?
|
| Critical Care | 1 | 2013 | 657 | 0.290 |
Why?
|
| Heart Failure | 4 | 2022 | 2297 | 0.260 |
Why?
|
| Chest Pain | 2 | 2023 | 129 | 0.260 |
Why?
|
| Risk Factors | 17 | 2025 | 10282 | 0.250 |
Why?
|
| United States | 17 | 2023 | 10905 | 0.250 |
Why?
|
| Ultrasonography, Interventional | 2 | 2024 | 192 | 0.240 |
Why?
|
| Peripheral Arterial Disease | 2 | 2021 | 291 | 0.240 |
Why?
|
| Angina, Unstable | 4 | 2006 | 53 | 0.230 |
Why?
|
| Veterans | 3 | 2021 | 1752 | 0.220 |
Why?
|
| Coronary Disease | 5 | 2016 | 675 | 0.220 |
Why?
|
| Hemodynamics | 3 | 2022 | 850 | 0.220 |
Why?
|
| Coronary Stenosis | 2 | 2021 | 78 | 0.220 |
Why?
|
| Theft | 1 | 2023 | 5 | 0.220 |
Why?
|
| Hospitals, Low-Volume | 2 | 2021 | 31 | 0.210 |
Why?
|
| Subclavian Artery | 1 | 2023 | 73 | 0.210 |
Why?
|
| Female | 33 | 2020 | 66709 | 0.200 |
Why?
|
| Coronary Restenosis | 3 | 2009 | 23 | 0.200 |
Why?
|
| Atrial Flutter | 1 | 2022 | 32 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 1266 | 0.200 |
Why?
|
| Risk Assessment | 7 | 2025 | 3454 | 0.200 |
Why?
|
| Reoperation | 3 | 2020 | 833 | 0.190 |
Why?
|
| Triage | 2 | 2020 | 136 | 0.190 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 500 | 0.190 |
Why?
|
| Embolization, Therapeutic | 3 | 2016 | 219 | 0.190 |
Why?
|
| Coronary Circulation | 4 | 2008 | 215 | 0.190 |
Why?
|
| Myocardium | 1 | 2007 | 1016 | 0.190 |
Why?
|
| Hemostasis, Surgical | 1 | 2001 | 37 | 0.190 |
Why?
|
| Atherectomy, Coronary | 2 | 2020 | 9 | 0.190 |
Why?
|
| Hypothermia | 1 | 2021 | 57 | 0.180 |
Why?
|
| Benchmarking | 1 | 2022 | 137 | 0.180 |
Why?
|
| Male | 34 | 2020 | 61429 | 0.180 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2022 | 50 | 0.180 |
Why?
|
| Ischemia | 2 | 2021 | 362 | 0.180 |
Why?
|
| Societies, Medical | 5 | 2023 | 695 | 0.180 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 170 | 0.170 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 89 | 0.170 |
Why?
|
| Pericarditis | 1 | 2020 | 42 | 0.170 |
Why?
|
| American Heart Association | 4 | 2023 | 322 | 0.170 |
Why?
|
| Pericardiocentesis | 1 | 2019 | 16 | 0.170 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 36 | 0.170 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 54 | 0.160 |
Why?
|
| Time Factors | 10 | 2021 | 6326 | 0.160 |
Why?
|
| Inpatients | 2 | 2020 | 499 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2020 | 493 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 84 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 728 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.160 |
Why?
|
| Giardiasis | 1 | 1998 | 10 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 192 | 0.150 |
Why?
|
| Middle Aged | 25 | 2020 | 26918 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 1112 | 0.150 |
Why?
|
| Clinical Competence | 5 | 2023 | 1003 | 0.150 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 160 | 0.150 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 140 | 0.150 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 1437 | 0.150 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 46 | 0.150 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 316 | 0.140 |
Why?
|
| Quality Improvement | 2 | 2020 | 641 | 0.140 |
Why?
|
| Echocardiography | 3 | 2019 | 1052 | 0.140 |
Why?
|
| Body Weight | 1 | 2001 | 989 | 0.140 |
Why?
|
| Hypertension | 3 | 2017 | 1329 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2018 | 378 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2018 | 334 | 0.140 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 172 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 460 | 0.130 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2006 | 7 | 0.130 |
Why?
|
| Diarrhea | 1 | 1998 | 317 | 0.130 |
Why?
|
| Atrial Pressure | 1 | 2016 | 6 | 0.130 |
Why?
|
| Heart Septum | 1 | 2016 | 54 | 0.130 |
Why?
|
| Balloon Valvuloplasty | 1 | 2016 | 25 | 0.130 |
Why?
|
| Fever | 1 | 1998 | 298 | 0.130 |
Why?
|
| Pandemics | 2 | 2020 | 1106 | 0.130 |
Why?
|
| Health Services Accessibility | 2 | 2011 | 606 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 294 | 0.120 |
Why?
|
| Heart Transplantation | 2 | 2020 | 860 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 122 | 0.120 |
Why?
|
| Severity of Illness Index | 7 | 2025 | 2906 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 672 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 659 | 0.120 |
Why?
|
| Comorbidity | 4 | 2020 | 1532 | 0.120 |
Why?
|
| Recurrence | 4 | 2022 | 1419 | 0.120 |
Why?
|
| Registries | 5 | 2021 | 1430 | 0.120 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 157 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2017 | 1369 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 357 | 0.120 |
Why?
|
| Weight Loss | 1 | 1998 | 481 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 372 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2019 | 3070 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 517 | 0.110 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 6595 | 0.110 |
Why?
|
| Echocardiography, Doppler | 2 | 2007 | 171 | 0.110 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2014 | 43 | 0.110 |
Why?
|
| Heart | 3 | 2023 | 728 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2016 | 263 | 0.110 |
Why?
|
| Medical Staff | 1 | 2013 | 7 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2013 | 20 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2016 | 233 | 0.110 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 85 | 0.110 |
Why?
|
| Nurse's Role | 1 | 2013 | 31 | 0.110 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 737 | 0.100 |
Why?
|
| Nurses | 1 | 2013 | 64 | 0.100 |
Why?
|
| Pharmacists | 1 | 2013 | 84 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 130 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1888 | 0.100 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2004 | 62 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2016 | 1256 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 298 | 0.100 |
Why?
|
| Emergencies | 1 | 2013 | 170 | 0.090 |
Why?
|
| Survival Rate | 5 | 2020 | 2057 | 0.090 |
Why?
|
| Tachycardia, Ventricular | 1 | 2014 | 192 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 221 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 1999 | 804 | 0.090 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 1025 | 0.090 |
Why?
|
| Transportation of Patients | 1 | 2011 | 54 | 0.090 |
Why?
|
| Time | 1 | 2011 | 92 | 0.090 |
Why?
|
| Aspirin | 3 | 2018 | 222 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2013 | 300 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2011 | 285 | 0.090 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 124 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 175 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1096 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2009 | 38 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 1239 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2022 | 217 | 0.080 |
Why?
|
| Heart Arrest | 1 | 2014 | 353 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 732 | 0.080 |
Why?
|
| Calcinosis | 2 | 2001 | 178 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2009 | 85 | 0.080 |
Why?
|
| Logistic Models | 2 | 2016 | 1809 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 1168 | 0.070 |
Why?
|
| Fibrinolysis | 1 | 2008 | 41 | 0.070 |
Why?
|
| Vascular Patency | 1 | 2008 | 214 | 0.070 |
Why?
|
| Retrospective Studies | 9 | 2021 | 16307 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1957 | 0.070 |
Why?
|
| Mortality | 2 | 2019 | 238 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 527 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 414 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2009 | 455 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 5168 | 0.060 |
Why?
|
| Hospitalization | 3 | 2020 | 1779 | 0.060 |
Why?
|
| Vasodilator Agents | 2 | 2004 | 204 | 0.060 |
Why?
|
| Equipment Safety | 2 | 2002 | 36 | 0.060 |
Why?
|
| Adult | 6 | 2018 | 29620 | 0.060 |
Why?
|
| Incidence | 3 | 2025 | 3137 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2786 | 0.060 |
Why?
|
| Heparin | 2 | 2007 | 224 | 0.060 |
Why?
|
| Nitroprusside | 1 | 2004 | 47 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 634 | 0.060 |
Why?
|
| Clinical Protocols | 2 | 2018 | 239 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2004 | 75 | 0.050 |
Why?
|
| Adenosine | 1 | 2004 | 127 | 0.050 |
Why?
|
| Wounds, Penetrating | 1 | 2004 | 141 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 131 | 0.050 |
Why?
|
| Europe | 2 | 2014 | 353 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 233 | 0.050 |
Why?
|
| Coma | 1 | 2021 | 56 | 0.050 |
Why?
|
| Mammary Arteries | 1 | 2001 | 29 | 0.050 |
Why?
|
| Ticlopidine | 1 | 2001 | 28 | 0.050 |
Why?
|
| Coronary Aneurysm | 1 | 2001 | 32 | 0.040 |
Why?
|
| Thrombin | 1 | 2001 | 60 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2001 | 115 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2021 | 133 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 1698 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 2816 | 0.040 |
Why?
|
| Prognosis | 5 | 2016 | 4628 | 0.040 |
Why?
|
| Atherectomy | 1 | 2020 | 12 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 88 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2020 | 51 | 0.040 |
Why?
|
| Cause of Death | 2 | 2016 | 474 | 0.040 |
Why?
|
| Aneurysm, False | 1 | 2001 | 103 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3570 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2019 | 19 | 0.040 |
Why?
|
| Heart Ventricles | 2 | 2021 | 768 | 0.040 |
Why?
|
| Vascular Calcification | 1 | 2020 | 57 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 224 | 0.040 |
Why?
|
| Specialization | 1 | 2020 | 75 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 339 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 110 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 174 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 2165 | 0.040 |
Why?
|
| Equipment Design | 2 | 2016 | 599 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2019 | 1179 | 0.040 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1999 | 86 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1999 | 74 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 3586 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 1999 | 133 | 0.040 |
Why?
|
| Thrombosis | 1 | 2003 | 525 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2020 | 249 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 382 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 443 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 601 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 525 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 2016 | 21 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 323 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 219 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2003 | 854 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 68 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 280 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2001 | 2100 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 639 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 385 | 0.030 |
Why?
|
| Ascites | 1 | 2016 | 88 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1287 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 143 | 0.030 |
Why?
|
| Edema | 1 | 2016 | 136 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 752 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 74 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2014 | 6152 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 490 | 0.030 |
Why?
|
| Curriculum | 1 | 2019 | 726 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2016 | 489 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 1307 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 287 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2009 | 1638 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2006 | 898 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 698 | 0.020 |
Why?
|
| Population Density | 1 | 2011 | 34 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2004 | 779 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 593 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3079 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 4811 | 0.020 |
Why?
|
| North America | 1 | 2011 | 240 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 185 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 285 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2006 | 1195 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2002 | 339 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 278 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 209 | 0.020 |
Why?
|
| Florida | 1 | 2008 | 78 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 554 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 873 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2009 | 240 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 103 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2007 | 760 | 0.010 |
Why?
|
| Protamines | 1 | 2004 | 13 | 0.010 |
Why?
|
| Constriction | 1 | 2004 | 50 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 435 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 1121 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 1109 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 1397 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 590 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 2003 | 22 | 0.010 |
Why?
|
| Acetylcholine | 1 | 2003 | 83 | 0.010 |
Why?
|
| Minnesota | 1 | 2002 | 133 | 0.010 |
Why?
|
| Microcirculation | 1 | 2003 | 95 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 237 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 754 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2003 | 172 | 0.010 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2001 | 42 | 0.010 |
Why?
|
| Heart Atria | 1 | 2003 | 316 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2002 | 308 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1999 | 14 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1999 | 25 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2001 | 168 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2006 | 1063 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 167 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 1999 | 158 | 0.010 |
Why?
|
| Exercise Test | 1 | 1999 | 253 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1999 | 151 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 1999 | 103 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 1504 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 680 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 3298 | 0.010 |
Why?
|